Text Size

Antiviral response in vernal keratoconjunctivitis may be protective against COVID-19

Leonardi A., Rosani U., Cavarzeran F., Daull P., Garrigue J.-S., Paola B.

  • 2021
  • Allergy: European Journal of Allergy and Clinical Immunology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Department of Neuroscience, Ophthalmology Unit, University of Padua, Padova, Italy; Department of Biology, University of Padova, Padova, Italy; Santen SAS, Evry, France; Department of Molecular Medicine, Histology Unit, University of Padova, Padova, Italy

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022